Advertisement

Können wir das Ansprechen auf die somatischen Therapien der Schizophrenie verbessern?

  • G. M. Simpson
  • D. F. Levinson
Chapter

Zusammenfassung

Die somatische Therapie der Schizophrenie zu verbessern, erfordert eine genaue Beachtung der Diagnose, die Wahl der optimalen Dosierung und der Dauer der Behandlug für den einzelnen Patienten.Diese Arbeit konzentriert sich auf die Diagnose und die medikamentöse Therapie. Neuroleptika bleiben die wichtigste somatische Beandlungsart für die Schizophrenie. Diese Behandlungen sollten im Zusammenhang mit dem gegenwärtigen Wissen und den Kontroversen hinsichlich der diagnostischen Kriterien, mit dem Krankheitsverlauf, mit den verschiedenen klinischen Erscheinungsformen, die auch verschiedene Krankheitstypen repräsentieren können, betrachtet werden.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literaturverzeichnis

  1. Astrup C, Vatten L. Effect of benzodiazepine derivative estazolam in schizophrenia. Biol Psychiatry 1984; 19: 85–88.PubMedGoogle Scholar
  2. Bleuler M. Long-term Patient and Family Studies. New Haven: Yale University Press, 1978.Google Scholar
  3. Campbell R, Simpson GM. Alternative approaches for psychotic agitation. Psychosomatics (im Druck).Google Scholar
  4. Carpenter WT, Heinrichs DW. Early intervention, time-limited, targeted pharmacotherapy of schizophrenia. Schizophr Bull 1983; 9: 533–543.PubMedCrossRefGoogle Scholar
  5. Childers RT. Comparison of four regimens in newly-admitted female schizophrenics. Am J Psychiatry 1964; 120: 1010–1011.PubMedGoogle Scholar
  6. Chouinard G, Jone BD. Neuroleptic-induced supersensitivity psychosis: Clinical and pharmacological characteristics. Am J Psychiatry 1980; 137: 16–21.PubMedGoogle Scholar
  7. Ciompi L. The natural history of schizophrenia in the longterm. Br J Psychiatry 1980; 136: 413–420.PubMedCrossRefGoogle Scholar
  8. Cooper TB, Simpson GM, Haher EJ, Berger P-EE. Butaperazine pharmacokinetics. I. Effect of dosage regimen on steady state blood levels. Arch Gen Psychiatry 1975; 32: 903–905.PubMedCrossRefGoogle Scholar
  9. Crane GE. High doses of trifluperazine and tardive dyskinesia. Arch Neurol 1970; 33: 176–180.CrossRefGoogle Scholar
  10. Ereshefsky L, Saklad SR, Jann MW, et al. Future of depot neuroleptic therapy: Pharmacokinetic and pharmacodynamic approaches. J Clin Psychiatry 1984; 45: 50–59.PubMedGoogle Scholar
  11. Foster MW, Gayle RP. Dangers in combining reserpine (Serpasil) with Ecr. Jama 1955; 159: 1520–1522.CrossRefGoogle Scholar
  12. Gagrat D, Hamilton J, Belmaker RH. Intravenous diazepam in the treatment of neurolepticinduced acute dystonia and akathisia. Am J Psychiatry 1978; 135: 1232–1233.PubMedGoogle Scholar
  13. Goldstein MJ. Individuelle and Familientherapie der Schizophrenie. In diesem Buch 1988: 190–218.Google Scholar
  14. GoOdnick PJ, Meltzer HY. Treatment of schizoaffective disorders. Schizophr Bull 1984; 10: 30–48.Google Scholar
  15. Gould RI, Murphy Kmm, Reynolds JJ, Snyder SH. Antischizophrenic drugs of the diphenylbutylpiperidine type act as calcium channel antagonists. Proceedings of the National Academy of Sciences 1983; 80: 5122–5125.CrossRefGoogle Scholar
  16. Haase HJ. Correlation between extrapyramidal symptoms and psychiatric states. In: Kline NS, ed. Psychopharmacology Frontiers. Boston: Little/Brown, 1959.Google Scholar
  17. Heinrichs DW, Cohen BP, Carpenter WT Jr. Early insight and the management of schizophrenic decompensation. J Nerv Ment Dis 1985; 173: 133–138.Google Scholar
  18. Herz MI, Szymanski HE, Simon JC. Intermittent medication for stable schizophrenic outpatients: An alternative to maintenance medication. Am J Psychiatry 1982; 139: 918–922.PubMedGoogle Scholar
  19. Hogarty GE, Schooler NR, Ulrich R, Mussare F, Ferro P, Herron E. Fluphenazine and social therapy in the aftercare of schizophrenic patients. Arch Gen Psychiatry 1979; 36: 1283–1294.CrossRefGoogle Scholar
  20. Kane JM, Rifkin A, Woerner M, et al. Low-dose neuroleptic treatment of outpatient schizophrenics: I. Preliminary results for relapse rates. Arch Gen Psychiatry 1983; 40: 893–896.PubMedCrossRefGoogle Scholar
  21. Kane JM. Antipsychotic drug side effects: their relationship to dose. J Clin Psychiatry 1985; 46: 16–21.PubMedGoogle Scholar
  22. Kellner R, Wilson RM, Muldawer MD, Bathak D. Anxiety in schizophrenia. The responses to chlordiazepoxide in an intensive designed study. Arch Gen Psychiatry 1975; 32: 1246–1254.PubMedCrossRefGoogle Scholar
  23. Klein E, Ental E, Lerer B, Belmaker RH. Carbamazepine and haloperidol vs placebo and haloperidol in excited psychoses. Arch Gen Psychiatry 1984; 41: 165–170.PubMedCrossRefGoogle Scholar
  24. Lecrubier Y. The hypodopaminergic theory and the use of energizing neuroleptics: A European perspective. Presented at the 23rd Annual Meeting of the American College of Neuropsychopharmacology, 1984.Google Scholar
  25. Levinson DF, Simpson GM. Neuroleptic-induced Eps with fever: Heterogeneity of the »neuroleptic malignant syndrome«. Arch Gen Psychiatry 1986; 43: 839–848.Google Scholar
  26. Marder SR, Hawes EM, Van Putten T, et al. Fluphenazine plasma levels in patients receiving low and conventional doses of fluphenazine decanoate. Psychopharmacology 1986; 88: 480–483.PubMedCrossRefGoogle Scholar
  27. Marder SR, Van PuTten T, Mintz J, et al. Costs and benefits of two doses of fluphenazine Arch Gen Psychiatry 1984; 41: 1025–1029.Google Scholar
  28. May Pra. Treatment of schizophrenia: A comparative study of five treatment methods. New York: Science House, 1968.Google Scholar
  29. May Pra, Dencker SJ, Hubbard JW, Midha KK, Liberman RP. Ein systematischer Ansatz zur Therapieresistenz schizophrener Erkrankungen. In diesem Buch 1988: 133–150.Google Scholar
  30. Mueser KT, Dysken MW. Narcotic antagonists in schizophrenia: A methodological review. Schizophr Bull 1983; 9: 213–225.CrossRefGoogle Scholar
  31. Ogura C, Kishimotg A, Nakao T. Clinical effect of L-dopa on schizophrenia. Curr Therap Res 1976; 20: 308–318.Google Scholar
  32. Peet M, Middlemiss DN, Yates RA. Pharmacokinetic interaction between propranolol and chlorpromazine in schizophrenic patients. Lancet, 1980; 2: 978.PubMedCrossRefGoogle Scholar
  33. PI EH, Miller A, Rosenberg MR, Schultz CL, Simpson GM. Therapeutic effects of psychiatric hospitalization. J Psychiatr Treatm Eval 1983; 5: 135–142.Google Scholar
  34. Schooler NR, Levine J, Severe JB, et al. Prevention of relapse in schizophrenia. Arch Gen Psychiatry 1980; 37: 16–24.PubMedCrossRefGoogle Scholar
  35. Simpson GM. Controlled studies of antiparkinsonism agents in the treatment of drug-induced extrapyramidal symptoms. Acta Psychiatr Scand 1970; 212: 44–51.CrossRefGoogle Scholar
  36. Simpson GM, Amuso D, Blair JH, Farkas T. Phenothiazine-produced extrapyramidal system disturbances. Arch Gen Psychiatry 1964; 10: 199–208.PubMedCrossRefGoogle Scholar
  37. Simpson GM, Levinson DF, Midha KK, et al. Abstract presented at IV World Congress of Biological Psychiatry. Philadelphia, 1985 a.Google Scholar
  38. Simpson GM, May Pra. Schizophrenic disorders. In: Treatment of Mental Disorders (im Druck).Google Scholar
  39. Simpson GM, Shrivastava RK. Abnormal gaits in TD. Am J Psychiatry 1978; 135: 865.PubMedGoogle Scholar
  40. Simpson GM, Yadalam K. Blood levels of neuroleptics: State of the art. J Clin Psychiatry 1985 b; 46: 22–28.Google Scholar
  41. Siris SG, Rifkin AE. Response of postpsychotic depression to adjunctive imipramine or amitriptyline. J Clin Psychiatry 1982; 43: 485–486.PubMedGoogle Scholar
  42. Smith K, Surphillis Wrp, Gynther MD. Ecr/chlorpromazine and chlorpromazine compared in the treatment of schizophrenia. J Nery Ment Dis 1967; 144: 284–290.CrossRefGoogle Scholar
  43. Taylor P, Fleminger JJ. Ect for schizophrenia. Lancet 1980; 1: 380–383.Google Scholar
  44. Van Putten T, May Pra. Subjective response as a predictor of outcome in pharmacotherapy. Arch Gen Psychiatry 1978; 35: 477–480.PubMedCrossRefGoogle Scholar
  45. Van Putten J, May Pra, Marder SR. Response to antipsychotic medication: The doctor’s and the consumer’s view. Am J Psychiatry 1984; 141: 16–19.Google Scholar
  46. Wilson JC, Garbutt JC, Lanier CF, Moylan J, Nelson W, Prange AJ Jr. Is there a tardive dyskinesia? Schizophr Bull 1983; 9: 187–191.Google Scholar
  47. Wistedt B, Wiles D, Kolakowska T. Slow decline of plasma drug and prolactin levels after discontinuation of chronic treatment with depot neuroleptics. Lancet 1981; 1: 1163.PubMedCrossRefGoogle Scholar
  48. Yorkston NJ, Zaki SA, Pitcher DR, Gruzelier JH, Hollander D, Sargeant Hgs. Pto-pranolol as an adjunct to the treatment of schizophrenia. Lancet 1977; 2: 575–578.PubMedCrossRefGoogle Scholar
  49. Zubenko GS, Cohen BM, Lipinski JF Jr, Jonas J. Use of clonidine in treating neurolepticinduced akathisia. Psychiatry Res 1984 a; 13: 253–259.Google Scholar
  50. Zubenko GS, Lipinski JF Jr., Cohen BM, Barreira PJ. Comparison of metoprolol and propranolol in the treatment of akathisia. Psychiatry Res 1984 b; 11: 143–149.Google Scholar

Copyright information

© Springer Fachmedien Wiesbaden 1988

Authors and Affiliations

  • G. M. Simpson
    • 1
  • D. F. Levinson
    • 1
  1. 1.Psychiatric InstituteMedical College of Pennsylvania at Eastern PennsylvaniaPhiladelphiaUSA

Personalised recommendations